Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic-dysfunction Associated Liver Disease (MASLD) Clear all

Conditions: MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
Interventions: Thermoacoustic Enhanced Ultrasound; Device
Lead sponsor: Endra Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Obesity, Overweight (BMI > 25)
Interventions: bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester), Placebo; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Interventions: ALN-HSD, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 61
States / cities: Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 47 more

Conditions: NASH/MASH, NAFLD/MASLD
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 139
States / cities: Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 117 more

Conditions: Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
Interventions: BMN 255, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Chula Vista, California • Chula Vista Isles, Florida + 4 more

Conditions: Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: ALN-PNP, Placebo (PB); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Glendale, California • Los Angeles, California • Miami, Florida + 2 more

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
Interventions: Semaglutide Pen Injector, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 10 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions: Pegozafermin, Placebo; Biological · Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 150
States / cities: Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions: LY3849891, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Chandler, Arizona • Orange, California • Rialto, California + 8 more

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions: Pegozafermin, Placebo; Biological · Other
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 154
States / cities: Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 132 more

Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Food Insecurity
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions: Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control); Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program; Procedure · Drug · Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease
Interventions: EHR alert; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions: Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B), Placebo (Cohort B); Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 48
States / cities: Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 41 more

Conditions: Type 2 Diabetes, Liver Disease
Interventions: Behavioral Treatment; Device
Lead sponsor: SIPPA Solutions INC; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Jamaica, New York

Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
Interventions: AI-Enabled Identification (EchoNet-Liver); Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028
U.S. locations: 6
States / cities: Los Angeles, California • Palo Alto, California • Pleasanton, California + 2 more

Conditions: MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions: MR exam, US exam, Blood draw, Physical measurements, Questionnaires; Diagnostic Test · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 9 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions: Low-oxalate fixed diet; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
Interventions: Not listed
Lead sponsor: Fibronostics USA, Inc; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Timeline: 2025
U.S. locations: 1
States / cities: Lady Lake, Florida

Search by objective public record fields.

Thermoacoustic Method for Estimating Liver Fat Fraction

Effect of Ketone Esters on Liver Fat Content and Metabolic Function

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Pediatric Metabolic Dysfunction-associated Steatotic Liver Disease and Food Insecurity

Isocaloric Navy-Bean Substitution in Adults With MASLD

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

Advanced Fibrosis Detection for MASLD in Primary Care

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk

Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)

Quantitative Ultrasound to Assess Steatotic Liver Disease in Children

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.